Back

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation.

28 August 2016 (13:05 - 13:25)
Organised by:
Congress Presentation Part of: A novel approach for high CV risk patients with diabetes: the potential of epigenetics Primary cardiovascular prevention: interventions and outcomes ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Jorge Plutzky

Brigham and Women's Hospital, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
Introduction - A novel approach for high CV risk patients with diabetes: the potential of epigenetics.
Professor S. Del Prato (Pisa, IT)
Presentation thumbnail
The high risk diabetes patient with cardiovascular disease: what else can we target to reduce cardiovascular risk?
Professor K. Ray (London, GB)
Presentation thumbnail
BET inhibition in cardiovascular disease: a new dawn?
Professor J. Kastelein (Amsterdam, NL)
Presentation thumbnail
Discussion & summary - A novel approach for high CV risk patients with diabetes: the potential of epigenetics.
Professor S. Del Prato (Pisa, IT) Professor K. Ray (London, GB)

Access the full session

Session thumbnail
A novel approach for high CV risk patients with diabetes: the potential of epigenetics

The Event

Event poster

ESC Congress 2016

28 August 2016 13:05 CET
You may be interested in
thumbnail
Congress Presentation
BET protein inhibition rewires the vascular-fat interface in cardiometabolic disease
29 August 2025
thumbnail
Congress Presentation
The biased angiotensin receptor 1-ligand TRV023 attenuates atherosclerosis through selective inhibition of Gq-mediated signaling
3 September 2019
thumbnail
Congress Presentation
Novel multidisciplinary cardiometabolic clinic in a UK tertiary cardiology centre: early activity, interventions and potential for cardiovascular risk optimisation
27 August 2021
thumbnail
Congress Presentation
Atherosclerotic cardiovascular events associated with BTK inhibitors: a systematic review and meta-analysis of harms
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources